Valganciclovir Prophylaxis
ApprovedSmall molecule
Valganciclovir Prophylaxis is one of 26 small molecule programs targeting Kidney Transplant. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
476 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Valganciclovir Prophylaxis
UUniversity of Guadalajara
Approved
Nulojix
Bristol-Myers SquibbPreclinical
Medrol
PfizerPreclinical
Zinbryta
RochePreclinical
Sensipar
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Cysteine Hydrochloride
NovartisPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Valganciclovir Prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Guadalajara